ERAS

Current Thesis

• Clinical-stage precision-oncology name functioning as a binary optionality vehicle on the RAS/MAPK pipeline. Two independent catalyst legs now timed within ~3 weeks: (a) AACR 2026 poster window 2026-04-25 to 04-30 (RAS(ON) platform read-through), (b) ERAS-0015 Ph1 readout narrowed to mid-May 2026 per company update 2026-04-21, (c) SEACRAFT-2 naporafenib Ph3 topline still guided 2026.
• Archetype confirmed 5 (Binary Catalyst) — not a narrative compound. This is a readout lottery against elevated short interest. The 2026-04-21 "narrowed timeline" PR is the first real information update since the halt and tightens the catalyst density into a 3-week window.
• The 2026-04-13 circuit-breaker halt at -11.52% is still unreconciled on the tape 9 sessions later. No 8-K, no equity-raise PR, no analyst note in the pull. The subsequent "narrowed readout" PR on 2026-04-21 reads as management trying to reset the narrative — possibly sufficient, possibly cover for a follow-on. Asymmetry of information argues against front-running.
• Posture: DORMANT / DO-NOT-INITIATE pre-AACR. Prior engine calls 2026-04-19 (DEFER MEDIUM dry-run). Reaffirming DEFER at LOW conviction; only arm a probe on a clean post-halt reclaim + explained 8-K.

Bull Case

• ERAS-0015 Ph1 data readout timeline narrowed to mid-May 2026 (PR 2026-04-21) — management only tightens guidance when data is in-hand. Historical biotech base rate: narrowed-window PRs within 30d of readout are weakly positive (management sandbagging rarely followed by a print-day whiff). Not a tell, but a datapoint.
• AACR 2026 (2026-04-25 to 04-30) poster window gives a first tradeable data flashpoint. Any RAS(ON) mechanistic or early-clinical signal in KRAS G12D (ERAS-4001) or pan-RAS (ERAS-0015) re-rates the platform vs. RVMD RMC-6236.
• Naporafenib / SEACRAFT-2 Ph3 (NRAS-mut 2L+ melanoma) is the company-maker. NRAS-mut = ~15-20% of melanoma with no approved targeted post-IO. Clean OS hit = 3-5x tape event on sub-$250M EV (pre-halt mark; needs refresh).
• Squeeze overlay: small float + historically elevated short interest into stacked catalysts = positive gamma on any benign surprise. If halt is explained away AND AACR poster lands, this is a classic a5/a6 combo setup.
• Cash runway previously guided into 2027+ — defers terminal dilution risk past SEACRAFT-2 topline IF reaffirmed on next Q1 call.

Bear Case

• 2026-04-13 halt, -11.52%, no public catalyst — 9 sessions of silence is itself the signal. Plausible reads, all -20% to -40% tape events on disclosure: (a) at-the-market / follow-on being shopped, (b) SEACRAFT-2 enrollment or safety pause pre-material-disclosure, (c) Kumquat/Joyo partner pulling a collab option. The 2026-04-21 "narrowed readout" PR could be the softener before the hard news.
• Narrowed-window PR cuts both ways: mid-May 2026 Ph1 readout = the binary window closes in ~3 weeks. If ERAS-0015 whiffs on RECIST or tolerability, there is no time to re-frame before SEACRAFT-2 topline — the platform thesis breaks and the cap-table has to finance through a broken narrative.
• Naporafenib tolerability overhang from Novartis-era LXH254 lineage (rash, photosensitivity, CK elevations). Realistic -40% scenario is stat-sig but messy Ph3.
• RAS(ON) field is crowded and we are behind: RVMD (RMC-6236) leads, BMY/Mirati and Roche better capitalized. ERAS-0015/4001 must differentiate on potency or tolerability; parity = platform gets ignored.
• Beta: ERAS trades ~1.5-2× XBI into risk-off. XBI trend MUST be re-checked pre-probe — any broad biotech drawdown compounds idiosyncratic risk.

Setup & Price Structure

• No price context supplied this run — same gap as 2026-04-19. Every level below is conditional on next refresh wiring in: last close, 20/50/200-DMA, ATR(14), short interest %, days-to-cover, post-halt volume profile, XBI relative strength.
• Reference tape event: 2026-04-13 circuit-breaker halt at -11.52%. Post-halt close defines the structural ceiling to reclaim; the 5-session range since defines the consolidation zone.
• No new price signal from 2026-04-21 PR — tape reaction to narrowed-readout guidance is the immediate tell (unseen this run).
• Conditional entry trigger (for next refresh with price data): only arm a probe IF ALL three of (a) 8-K or PR explains the halt benignly, (b) stock reclaims pre-halt close on >2× 20-day avg volume, (c) XBI is above its 20-DMA. Otherwise skip until AACR posters print.
• Position sizing if triggered: a5 binary → max 1.5-2% of book, hard stop at post-halt low minus 1 ATR. No averaging down. No overnight hold into Ph1 readout if initiated pre-mid-May.

Catalyst Calendar (next 30 days)

• 2026-04-25 to 2026-04-30 — AACR Annual Meeting 2026. RAS(ON) franchise poster window. ERAS-0015 and ERAS-4001 abstracts expected. Competitor read-across: RVMD RMC-6236, BMY Mirati, Roche pan-RAS updates on same tape.
• ~2026-05-06 to 2026-05-20, est. — ERAS-0015 Ph1 data readout (narrowed to mid-May per PR 2026-04-21). First tradeable clinical datapoint for the RAS(ON) platform.
• ~2026-05-06 to 2026-05-15, est. — Q1 2026 earnings call (small-cap biotech pattern). Expect: SEACRAFT-2 enrollment update, cash runway reaffirm-or-cut, halt context if not already 8-K'd. Flatten any position 3 trading days prior.
• Ongoing — 8-K watch for the 2026-04-13 halt explanation. No filings in the pull as of 2026-04-22. Longer the silence, higher the probability of a dilutive or enrollment-negative disclosure.

What Would Change Our Mind

• Bull trigger (upgrade to HIGH, arm a 2% probe): benign 8-K or PR reconciling the 2026-04-13 halt (e.g., technical trading halt, lifted partnership NDA) + AACR poster with clean RECIST response or durable PFS signal in ERAS-0015/4001 + weekly close back above pre-halt range on >2× volume + XBI above 20-DMA.
• Bear trigger (stay DORMANT, move to DO-NOT-TOUCH): 8-K within 30 days discloses dilutive equity raise, SEACRAFT-2 enrollment pause, safety hold, or cash runway cut below Q4 2026. OR ERAS-0015 mid-May readout shows <15% ORR or dose-limiting tolerability. OR RVMD RMC-6236 AACR data dominates the RAS(ON) tape on same session.
• Structural invalidation: weekly close fails to reclaim pre-halt range on rising volume by end of AACR week (2026-05-01 close).
• Meta-trigger: if 8-K lands mid-AACR and tape gaps down >10%, the thesis is over — no re-entry until SEACRAFT-2 topline re-rates the cap table.

Correlation Notes

• Primary beta: XBI (SPDR S&P Biotech) — ERAS historically 1.5-2× on risk-off sessions. Broad biotech regime must be checked before any probe.
• Direct readthroughs: RVMD (Revolution Medicines — RMC-6236, ahead in RAS(ON)), BMY (Mirati legacy KRAS), RHHBY (Roche pan-RAS). AACR poster session same-day correlations will be high and bidirectional.
• Indirect readthroughs: IOVA, NKTR, other NRAS-melanoma / post-IO adjacent names trade in sympathy on SEACRAFT-2 news. Not pair-trade quality but situational awareness.
• Theme membership: rare-disease-approvals (currently MATURING per 2026-04-21 theme update). No longer tagged ras-oncology or small-cap-biotech-binary in the registry — that downgrade slightly lowers the structural tailwind coming in.
• Macro: 10Y yield and XBI inverse correlation still dominant for unprofitable biotech. Any yield-spike risk-off event compounds the halt uncertainty — another reason to wait for post-halt structure to resolve before initiating.